Abstract:Abstract Background Recent results from our prospective multi-center study identified patients with t (8; 21) AML as high-risk according to their MRD status after the second consolidation chemotherapy and allo-HSCT can benefit this part of patients; however, the relapse rate was reported to be 22% even after allo-HSCT for those high-risk patients. To date, there have been no studies to answer the question of whether the specific fusion gene, RUNX1/RUNX1T1 can be used to further distinguish between patients with low and high risks of relapse in allo-HSCT setting, just like the already established standard for MRD measurement in CML and APL. Methods Sixty consecutive AML patients with t (8; 21) and identified as high-risk according to the criteria from our recently published report patients who received allo-HSCT were enrolled between January 2006 and January 2013. Serial MRD monitoring by RQ-PCR post HSCT was done. The impact of MRD monitoring on transplant outcomes was assessed. Results A > 3 log reduction at 1 month after HSCT in RUNX1/RUNX1T1 transcripts from diagnosis, is associated with 2-year CIR of 17% in the 88% of patients achieving it, compared with 43% in the remaining (p=.02). A > 3 log reduction at 2 months after HSCT in transcripts from diagnosis, is associated with a CIR of 9% and LFS of 66% in the 86% of patients achieving it, compared with CIR of 100% and LFS of 0% in the remaining (both p<.001). A > 3 log reduction at 3 months after HSCT in RUNX1/RUNX1T1 transcripts from diagnosis, is associated with a CIR of 11% and LFS of 73% in the 78% of patients achieving it, compared with CIR of 44% and LFS of 0% in the remaining (both p<.001). Of the 60 patients analyzed, 28 patients had positive MRD, occurring at a median of 110 days (30-540 days) after transplant. The predictive value of sequential monitoring could be demonstrated in 8 patients culminating in clinical relapse (representing 73% of all relapsing patients). The median time from MRD positivity in BM to morphological relapse was 95 days (range, 33-140 days). Conclusions A > 3 log reduction at the first 3 months after HSCT in RUNX1/RUNX1T1 transcripts from diagnosis is highly prognostic. We conclude that MRD monitoring by RQ-PCR at regular early time points post HSCT in t (8; 21) AML allows further identification of patients at high risk of relapse even after allo-HSCT and could now be incorporated in clinical trials to evaluate the role of risk directed prophylactic/preemptive therapy. This work was partly supported by The Key Program of National Natural Science Foundation of China £¨Grant No. 81230013£©, Beijing Municipal Science & Technology Commission (No.Z121107002812033) and Bejing Municipal Science & Technology Commission£¨No.Z111107067311070). Disclosures: No relevant conflicts of interest to declare.

[Monitoring AML1-ETO Mrna Levels by Real-Time Quantitative RT-PCR in T(8;21) Acute Myeloid Leukemia Patients after Hematopoietic Stem Cell Transplantation].

Clinical Significance of AML/ETO Fusion Gene Mrna in Acute Myelogenous Leukemia.

[Monitoring Bcr-Abl Mrna Levels by Real-Time Quantitative RT-PCR in Chronic Myeloid Leukemia Patients after Hematopoietic Stem Cell Transplantation].

[Clinical Significance of Detection of AML1/ETO Fusion Transcripts in Childhood AML Using Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction].

Monitoring the AML1/ETO Fusion Transcript to Predict Outcome in Childhood Acute Myeloid Leukemia.

Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia with T(8;21)(q22;q22)

Real-time Reverse-Transcriptase Polymerase Chain Reaction in Monitoring BCR/ABL Transcript Levels in Chronic Myeloid Leukemia Patients after Allogeneic Hematopoietic Stem Cells Transplantation

[Follow Up Detection of AML/ETO Fushion Transcripts after Chemotherapy or Bone Marrow Transplantation in Leukemia Patients]

Minimal Residual Disease Monitoring By Quantitative RT-PCR In t (8; 21) AML Early After Allogeneic HSCT Can Predict Clinical Outcomes and Allow Further Risk Stratification

Clinical Significance of Monitoring ETV6-RUNX1 Fusion Gene Expression in Children with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Outcome and Minimal Residual Disease Monitoring in Patients with T(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

The Significance of Serial Monitoring of Bcr-Abl Transcripts Levels after Allogeneic Hematopoietic Stem Cell Transplantation in Screening Chronic Myeloid Leukemia Patients with Low Relapse

Clinical Value of Acute Myeloblastic Leukemia 1-ETO Fusion Transcripts in Children with Acute Myeloblastic Leukemia by Using Real-Time Quantitative Reverse Transcriptase Polymerase Chain Reaction

Expression and significance of BCR-ABL mRNA in chronic myeloid leukemia patients by qPCR

[Significance of Quantitative Detection of Bcr-Abl Mrna in Chronic Myeloid Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplant].

Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients]

Detection of Translocation ETS Leukemia-Acute Myeloid Leukemia1 Fusion Gene in Acute Lymphoblastic Leukemia Children by Real-Time Fluorescent Quantitative Polymerase Chain Reaction and Its Clinical Significance

[Clinical Significance of Monitoring E2A- PBX1 Fusion Gene Expression in Patients with Allogeneic Hematopoietic Stem Cell Transplantation].

Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome

Real-time Quantitative PCR Monitoring of Minimal Residual Disease in CML after Treatment

Combined usage of Wilms' tumor gene quantitative analysis and multiparameter flow cytometry for minimal residual disease monitoring of acute myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation